

Customized Workflows Accelerate Immunoassay Development with High-Content Biophysics and Modeling


“Unlocking High-Throughput Biology”

Carterra 2025 Symposium Series
Boston, MA 06 May 2025

Wesley Errington, PhD
Sr. Scientist, Antibody Development
R&D Systems, Bio-Techne

Expertise that Runs Deep

High-Quality Reagents, Analytical Instruments, and Precision Diagnostics



The antibody business unit generates content for businesses and applications across Bio-Techne and externally as Custom Services

Our antibodies enable gold-standard immunoassays

Proteins used as immunogens are expressed in mammalian cells to produce full length, properly folded, properly glycosylated, bioactive antigens

Our unique position enables us to better meet the specialized needs of our customers

R&D Systems Antibodies

Top-performing Molecular Toolsets

400,000

Antibody Products

200,000

Peer-reviewed Citations

100,000

Proprietary Clones

10,000

Clones tested by Advanced Verification of specificity


42

Validated Applications

70

Species

Destination of Choice



R&D Systems Antibodies

Antibody Reagents Power Immunoassay Technologies

400,000

Antibody Products

200,000

Peer-reviewed Citations

100,000

Proprietary Clones

10,000

Clones tested by Advanced
Verification of specificity

42

Validated Applications

70


Species

Destination of Choice

ANTIBODIES



PROTEINS



IMMUNOASSAYS



INSTRUMENTS


R&D SYSTEMS

NOVUS
BIOLOGICALS

proteinsimple

Information-rich HT-SPR Enhances Design and Development


Making the Invisible Visible through the Lens of SPR



Information-rich HT-SPR Enhances Design and Development

Simulated SPR to Drive the Design, Build, Test of Complex Molecular Tools

Programming Info-rich SPR-based Modeling – simulating dynamic systems




Bruncics B., Errington W.J., et. al. (2022) *Nat. Comm.*

Information-rich HT-SPR Enhances Design and Development

Simulated SPR to Drive the Design, Build, Test of Complex Molecular Tools

Programming Info-rich SPR-based Modeling – exploring unreachable spaces




Bruncics B., Errington W.J., et. al. (2022) *Nat. Comm.*


Information-rich HT-SPR Enhances Design and Development

Enhancing Development Pipelines with High-content Biophysical Platforms

- SPR (Surface Plasmon Resonance) Physics
- Antibody–Antigen Binding Seen in Real-Time





- Simultaneous Analysis of 384 Antibodies
- Assess 150,000 Candidate Matched Pairs





Information-rich HT-SPR Enhances Design and Development

Surrounding our Extensive Antibody Content with Information-rich Datasets

- Understanding Antibodies through Kinetics
- Clustering Indicates Similarities/Diversity





- Epitope Binning Localizes Antibody Binding
- Structure-Guided Analysis IDs Candidates




Information-rich HT-SPR Enhances Design and Development

Customized Data Analytics Drive Decision-making and Solutions


- Integrate Structure and Kinetic Datasets
- Score Attributes for Target Assay Application




- Rank Formulations for Predicted Performance
- Leads Move Downstream to Development



High-Throughput Antibody Development Workflows





High-Throughput Antibody Development Workflows





High-Throughput Antibody Development Workflows

70 candidate **Detect Abs**



70 candidate **Capture Abs**




 70 candidate **Detect Abs**




High-Throughput Antibody Development Workflows



High-Throughput Antibody Development Workflows



High-Throughput Antibody Development Workflows




High-Throughput Antibody Development Workflows

01 // Unlocking the Antibody Vault

Our Workflow Leverages Our Extensive Collection for Immunoassay Development. ■ Antibodies utilized in our workflows derive from a variety of methods, designed immunogens, and hosts, and comprise hybridoma and recombinant monoclonals, and natural and designed polyclonals. ■ Evaluating large collections of antibodies significantly increases the success rate of demanding immunoassay development. ■ To fully leverage this antibody content, next-gen methodologies are required that afford both depth of analysis and speed to thoroughly and efficiently survey an expansive combinatorial landscape of possibilities.






	C	I	H	A		C	I	H	A		C	I	H	A
023						059					095			
024						060					096			
025						061					097			
026						062					098			
027						063					099			
028						064					100			
029						065					101			
030						066					102			
031						067					103			
032						068					104			
033						069					105			
034						070					106			
035						071					107			
036						072					108			
037						073					109			
038						074					110			
039						075					111			
040						076					112			
041						077					113			
042						078					114			
043						079					115			
044						080					116			
045						081					117			
046						082					118			
047						083					119			
048						084					120			
049						085					121			
050						086					122			
051						087					123			
052						088					124			
053						089					125			
054						090					126			
055						091					127			
056						092					128			
057						093					129			
058						094					130			



High-Throughput Antibody Development Workflows

02 // High-Content Biophysics

Antibody Biophysics and Biomarker Interaction Establish the Lead Landscape. ■ High-performance assay specifications derive from a variety of engineered optimizations unique to each platform. ■ Principal among these is the selection of matched-pairs of capture and detection antibodies. These matched-pairs require optimal attributes for the specifications of a particular immunoassay. ■ Our workflow produces expansive datasets that are utilized to populate information-rich landscapes that describe all combinations and permutations of assay performance design element such as antibody pairing, titer, sample type, and incubation time.





High-Throughput Antibody Development Workflows

03 // Navigating the Design Space

Modeling Drives Combinatorial Immunoassay Design. ■ Our approach synthesizes **1.** our domain-knowledge, as a deterministic rule layer; and **2.** intelligently-guided combinatorial formulation, as a metaheuristic search layer; to **3.** navigate the high-dimensional search space to uncover immunoassay combinations with properties simultaneously optimized for multiple specifications.



- | | |
|---------------|-----------------|
| 1 sensitivity | 4 precision |
| 2 epitope | 5 dynamic range |
| 3 specificity | ⚡ custom specs |



High-Throughput Antibody Development Workflows

04 // Data Integration & Modeling





Our Algorithmic Process Scores and Filters the Landscape to Identify Top Leads. ■ Information regarding the degree to which each antibody and composite combination possess the requisite performance is contained within our generated landscapes. ■ Through data analytics and modeling, the combinatorial landscape is efficiently scored and parsed. Integration of our 1. extensive collection of target-specific antibodies, 2. high-content biophysical data collection methodologies, and 3. model-guided performance predictors enable rapid identification of the top immunoassay leads, out of more than 50,000 enumerated and evaluated candidates. ■ These 20 curated leads are immediately directed to assay platform-specific validation.



High-Throughput Antibody Development Workflows



05 // Discovered Lead Validation

Curated Leads Accelerate Development of High-Sensitivity Immunoassay. ■ To illustrate the performance of our workflow, here we evaluated 20 curated lead combinations according to the high-performance specifications of the Simple Plex Ella assay platform. ■ This assay development process involves a sequence of specific tests, including core performance criteria such as **1.** quantification of the detectability dose-response profile; **2.** assessment of the quantitative limits of detection; **3.** detectability of endogenous levels of natural samples, and **4.** statistical precision. LF02 and LF11 were rapidly validated for all benchmarks.




High-Throughput Antibody Development Workflows

The Performance Advantage





High-Throughput Antibody Development Workflows


Extended Solutions – IVD Epitope Mapping



Extended Solutions – PK/PD Assay Design




Thank you



Thank you

R&D SYSTEMS™


biotechne®

Accelerating Antibody Matched-Pair Discovery and Immunoassay Development with High-Content Biophysics and ModelingWesley Errington, Ben Delebo, Alex Kalyuzhny and Nidhi Nath
R&D Systems, a biotechne brand, Custom Antibody Reagent Solutions, Minneapolis, MN**Overview**

- The continuous need for immunoassays with enhanced performance imposes increasing demands on both the antibody reagents and pipelines that power assay development.
- Significant development bottlenecks arise from low-throughput processes and unclear relationships between molecular antibody attributes and assay performance specifications.
- Our approach accelerates immunoassay and matched-pair development with extensive antibody collections, information-rich datasets, and modeling to navigate multifactor landscapes and deliver enhanced sensitivity and precision.

**01 // Unlocking the Antibody Vault**

Our Workflow Leverages Our Extensive Collection for Immunoassay Development. ■ Antibodies utilized in our workflows derive from a variety of methods, designed immunogens, and hosts, and comprise hybridoma and recombinant monoclonals, and natural and designed polyclonals. ■ Evaluating large collections of antibodies significantly increases the success rate of demanding immunoassay development. ■ To fully leverage this antibody content, next-gen methodologies are required that afford both depth of analysis and speed to thoroughly and efficiently survey an expansive combinatorial landscape of possibilities.

**04 // Data Integration & Modeling**

Our Algorithmic Process Scores and Filters the Landscape to Identify Top Leads. ■ Information regarding the degree to which each antibody and composite combination possess the requisite performance is contained within our generated landscapes. ■ Through data analytics and modeling, the combinatorial landscape is efficiently scored and parsed. Integration of our 1. extensive collection of target-specific antibodies, 2. high-content biophysical data collection methodologies, and 3. model-guided performance predictors enable rapid identification of the top immunoassay leads, out of more than 50,000 enumerated and evaluated candidates. ■ These 20 curated leads are immediately directed to assay platform-specific validation.

